Meagan Fansler, NP
Family · Columbia, MONPI 1720715485
Payments from drug & device makers
Across 327 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$746
- Sanofi$686
- Boehringer Ingelheim$524
- GSK$404
- United Therapeutics Corporation$290
- plus $3K from 27 others
What the payments were for
- Food & beverage$6,54599%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 69 | $1,454 |
| Regeneron Healthcare Solutions, Inc. | 27 | $746 |
| Sanofi | 33 | $686 |
| Boehringer Ingelheim | 22 | $524 |
| GSK | 23 | $404 |
| United Therapeutics Corporation | 14 | $290 |
| Grifols USA, LLC | 22 | $276 |
| Jazz Pharmaceuticals Inc. | 14 | $271 |
| Genentech USA, Inc. | 13 | $263 |
| Electromed, Inc. | 23 | $234 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $223 |
| Viatris Specialty LLC | 11 | $211 |
| Mallinckrodt Hospital Products Inc. | 7 | $145 |
| Amgen | 7 | $130 |
| Philips North America LLC | 5 | $87 |
| Baxter Healthcare | 3 | $66 |
| Bayer | 4 | $63 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| Mylan Specialty L.p. | 3 | $55 |
| Resmed Corp | 3 | $50 |
| Actelion Pharmaceuticals US, Inc. | 2 | $48 |
| Merck | 2 | $44 |
| Verona Pharma, Inc. | 2 | $37 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Harmony Biosciences LLC | 2 | $30 |
| Intuitive Surgical | 1 | $30 |
| Biomerieux Inc | 1 | $29 |
| Breas Medical, Inc. | 2 | $24 |
| Pfizer | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,605 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Spiriva RespimatTiotropium Bromide | 86 | $58,282 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $50,751 |
| SymbicortBudesonide/Formoterol Fumarate | 102 | $30,377 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $30,161 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $25,782 |
| Advair HfaFluticasone Propion/Salmeterol | 50 | $24,073 |
| Incruse ElliptaUmeclidinium Bromide | 49 | $20,627 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $13,831 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $10,473 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 46 | $6,735 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 25 | $6,635 |
| Atrovent HfaIpratropium Bromide | 14 | $6,433 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 46 | $6,065 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 217 | $5,058 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 12 | $3,642 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arexvy | $404 | $114,267207 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $524 | $72,113115 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $1,454 | $60,537145 claims |
| PfizerAbrysvo | $22 | $3,64212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.
Other family in Columbia
- Marcy MarkesColumbia$92K
- Jennifer GriggColumbia$46K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Laura HedigerSpringfield$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.